产品
编 号：F746042
产品类型
规格
价格
是否有货
结构图
CAS No: 1608122-71-9
产品详情
生物活性：
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with na?ve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary.
体内研究：
Tamtuvetmab (5 mg/mL, 7.5-30 mL; 静脉注射; 注射 15-30 分钟) 对患有幼稚 T 细胞淋巴瘤 (LSA) 的狗有体内疗效，但会导致呕吐、体重减轻、腹泻、嗜睡、食欲下降和厌食。Animal Model:T-cell LSA Model in Dog
Dosage:5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL
Administration:Intravenous injection; 15-30 min
Result:Showed in vivo efficacy with severe side effect.
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with na?ve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary.
体内研究：
Tamtuvetmab (5 mg/mL, 7.5-30 mL; 静脉注射; 注射 15-30 分钟) 对患有幼稚 T 细胞淋巴瘤 (LSA) 的狗有体内疗效，但会导致呕吐、体重减轻、腹泻、嗜睡、食欲下降和厌食。Animal Model:T-cell LSA Model in Dog
Dosage:5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL
Administration:Intravenous injection; 15-30 min
Result:Showed in vivo efficacy with severe side effect.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备